Trial · NCT00849121
Adverse events86
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 86
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction | Immune system disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 1 | 8 | 1 |
| other | Allergic reaction | Immune system disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 2 | 9 | 2 |
| other | Hypertension | Cardiac disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 1 | 8 | 2 |
| other | Hypertension | Cardiac disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 0 | 9 | 0 |
| other | Fatigue | General disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 3 | 8 | 3 |
| other | Fatigue | General disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 2 | 9 | 2 |
| other | Chills | General disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 3 | 8 | 4 |
| other | Chills | General disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 0 | 9 | 0 |
| other | Fever without neutropenia | General disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 1 | 8 | 1 |
| other | Fever without neutropenia | General disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 1 | 9 | 1 |
| other | Injection site reaction | General disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 8 | 8 | 47 |
| other | Injection site reaction | General disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 8 | 9 | 89 |
| other | Rash | Skin and subcutaneous tissue disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 2 | 8 | 2 |
| other | Rash | Skin and subcutaneous tissue disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 2 | 9 | |
| other | Hot flashes | Endocrine disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 1 | 8 | 1 |
| other | Hot flashes | Endocrine disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 1 | 9 | 1 |
| other | Heart burn | Gastrointestinal disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 1 | 8 | 1 |
| other | Heart burn | Gastrointestinal disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 1 | 9 | 1 |
| other | Constipation | Gastrointestinal disorders | 1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12 | 2 | 8 | 2 |
| other | Constipation | Gastrointestinal disorders | 2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12 | 0 | 9 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00849121/events